-
公开(公告)号：US20130095123A1
公开(公告)日：2013-04-18
申请号：US13656681
申请日：2012-10-20
发明人： Hans-Georg Lerchen , Lars Linden , Sherif El Sheikh , Willuda Willuda , Charlotte Christine Kopitz , Joachim Schuhmacher , Simone Greven , Christoph Mahlert , Beatrix Stelte-Ludwig , Sven Golfier , Rudolf Beier , Iring Heisler , Axel Harrenga , Karl-Heinz Thierauch , Sandra Bruder , Heike Petrul , Hannah Jörißen , Sandra Borkowski
CPC分类号： A61K47/48715 , A61K31/40 , A61K31/4025 , A61K31/404 , A61K31/422 , A61K31/4245 , A61K31/5355 , A61K31/536 , A61K31/537 , A61K31/5377 , A61K39/3955 , A61K45/06 , A61K47/542 , A61K47/6803 , A61K47/6851 , A61K47/6859 , A61K47/6869 , A61K47/6889 , A61K47/6891 , C07K5/06 , C07K5/06052 , C07K7/02 , C07K7/06 , C07K16/18 , C07K16/2812 , C07K16/2863 , C07K16/30 , C07K2317/565 , C07K2317/76
摘要： The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target C4.4a, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures.
摘要翻译： 本申请涉及针对目标C4.4a的N，N-二烷基硫酸钠的新粘合剂 - 药物共轭物（ADC），这些ADC的活性代谢物，制备这些ADC的方法，使用这些ADC 治疗和/或预防疾病，以及使用这些ADC用于制备用于治疗和/或预防疾病的药物，更具体地说是过度增殖和/或血管生成疾病，例如癌症疾病。 这样的治疗可以作为单一疗法来实施，或者与其它药物组合或进一步的治疗措施。
-
公开(公告)号：US20140322220A1
公开(公告)日：2014-10-30
申请号：US14359663
申请日：2012-11-22
发明人： Axel Harrenga , Charlotte Christine Kopitz , Stefanie Hammer , Frank Dittmer , Sven Golfier , Mark Trautwein , Sandra Bruder , Juergen Franz , Beatrix Stelte-Ludwig , Lars Linden , Ricarda Finnern , Simone Greven , Jan Tebbe
IPC分类号： C07K16/28 , A61K45/06 , A61K47/48 , A61K39/395
CPC分类号： C07K16/2863 , A61K39/3955 , A61K45/06 , A61K47/6849 , A61K2039/505 , C07K16/30 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/75 , C07K2317/92
摘要： The present invention provides antibodies, or antigen-binding antibody fragments thereof, or variants thereof which reduce the cell surface expression of FGFR2 after binding to FGFR2 in both cells overexpressing FGFR2 and cells expressing mutated FGFR2. Also provided are antibody-based therapies for FGFR2-related diseases or conditions such as cancer. Antibodies of the invention also can be used in the diagnostics field. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.
摘要翻译： 本发明提供抗体或其抗原结合抗体片段或其变体，其在过表达FGFR2的两个细胞和表达突变的FGFR2的细胞中结合FGFR2之后降低FGFR2的细胞表面表达。 还提供了用于FGFR2相关疾病或诸如癌症的病症的基于抗体的疗法。 本发明的抗体也可用于诊断领域。 本发明还提供了编码前述抗体的核酸序列，含有该抗体的载体，药物组合物和具有使用说明书的试剂盒。
-
公开(公告)号：US10781263B2
公开(公告)日：2020-09-22
申请号：US15923766
申请日：2018-03-16
发明人： Antje Kahnert , Kerstin Unterschemmann , Iring Heisler , Charlotte Christine Kopitz , Joachim Schuhmacher
摘要： The present invention provides immunoconjugates composed of antibodies, e.g., monoclonal antibodies, or antibody fragments that bind to mesothelin, that are conjugated to cytotoxic agents, e.g., maytansine, or derivatives thereof, and/or co-administered or formulated with one or more additional anti-cancer agents. The immunoconjugates of the invention can be used in the methods of the invention to treat and/or diagnose and/or monitor cancers, e.g. solid tumors, recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 40 kDa mesothelin polypeptide, which is overexpressed in several tumors, such as pancreatic and ovarian tumors, mesothelioma and lung cancer cells.
-
公开(公告)号：US20180201690A1
公开(公告)日：2018-07-19
申请号：US15923766
申请日：2018-03-16
发明人： Antje Kahnert , Kerstin Unterschemmann , Iring Heisler , Charlotte Christine Kopitz , Joachim Schuhmacher
摘要： The present invention provides immunoconjugates composed of antibodies, e.g., monoclonal antibodies, or antibody fragments that bind to mesothelin, that are conjugated to cytotoxic agents, e.g., maytansine, or derivatives thereof, and/or co-administered or formulated with one or more additional anti-cancer agents. The immunoconjugates of the invention can be used in the methods of the invention to treat and/or diagnose and/or monitor cancers, e.g. solid tumors, recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 40 kDa mesothelin polypeptide, which which is overexpressed in several tumors, such as pancreatic and ovarian tumors, mesothelioma and lung cancer cells.
-
公开(公告)号：US08992932B2
公开(公告)日：2015-03-31
申请号：US13656681
申请日：2012-10-20
发明人： Hans-Georg Lerchen , Lars Linden , Sherif El Sheikh , Jörg Willuda , Charlotte Christine Kopitz , Joachim Schuhmacher , Simone Greven , Christoph Mahlert , Beatrix Stelte-Ludwig , Sven Golfier , Rudolf Beier , Iring Heisler , Axel Harrenga , Karl-Heinz Thierauch , Sandra Bruder , Heike Petrul , Hannah Jöriβen , Sandra Borkowski
IPC分类号： A61K39/00 , A61K38/04 , C07K5/00 , C07K7/00 , C07K16/00 , C07K17/00 , C07K17/14 , C12P21/08 , A61K39/395 , A61K47/48 , C07K16/18 , A61K45/06 , C07K5/06 , C07K7/06 , C07K16/30 , C07K7/02
CPC分类号： A61K47/48715 , A61K31/40 , A61K31/4025 , A61K31/404 , A61K31/422 , A61K31/4245 , A61K31/5355 , A61K31/536 , A61K31/537 , A61K31/5377 , A61K39/3955 , A61K45/06 , A61K47/542 , A61K47/6803 , A61K47/6851 , A61K47/6859 , A61K47/6869 , A61K47/6889 , A61K47/6891 , C07K5/06 , C07K5/06052 , C07K7/02 , C07K7/06 , C07K16/18 , C07K16/2812 , C07K16/2863 , C07K16/30 , C07K2317/565 , C07K2317/76
摘要： The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target C4.4a, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practiced as a monotherapy or else in combination with other medicaments or further therapeutic measures.
摘要翻译： 本申请涉及针对目标C4.4a的N，N-二烷基硫酸钠的新粘合剂 - 药物共轭物（ADC），这些ADC的活性代谢物，制备这些ADC的方法，使用这些ADC 治疗和/或预防疾病，以及使用这些ADC用于制备用于治疗和/或预防疾病的药物，更具体地说是过度增殖和/或血管生成疾病，例如癌症疾病。 这样的治疗可以作为单一疗法来实施，或者与其它药物组合或进一步的治疗措施。
-
公开(公告)号：US20150023989A1
公开(公告)日：2015-01-22
申请号：US14364203
申请日：2012-12-12
发明人： Hans-Georg Lerchen , Stefanie Hammer , Axel Harrenga , Charlotte Christine Kopitz , Carl Friedrich Nising , Anette Sommer , Beatrix Stelte-Luowig , Christoph Mahlert , Joachim Schuhmacher , Sven Golfier , Simone Greven , Sandra Bruder
CPC分类号： A61K38/05 , A61K47/6849
摘要： The present application relates to new antibody drug conjugates (ADCs) of N,N dialkylauristatins directed against the target FGFR2, drug metabolites of said ADCs, a method for producing said ADCs, the use of said ADCs for the treatment and/or prevention of illnesses as well as the use of said ADCs for producing pharmaceuticals for the treatment and/or prevention of illnesses, particularly of hyperproliferative and/or angiogenic diseases such as carcinosis. Such treatments can be carried out as monotherapy or in combination with other pharmaceuticals or additional therapeutic measures.
摘要翻译： 本申请涉及针对靶FGFR2的N，N二烷基硫酸钠的新抗体药物共轭物（ADC），所述ADC的药物代谢物，所述ADC的制备方法，所述ADC用于治疗和/或预防疾病 以及使用所述ADC用于生产用于治疗和/或预防疾病，特别是过度增生和/或血管生成疾病如癌症的药物。 这样的治疗可以作为单一疗法或与其它药物或其它治疗措施结合进行。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.04 秒)
